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A Novel Class of Small Functional Peptides
that Bind and Inhibit Human -Thrombin
Isolated by mRNA Display
tide, mediated by the antibiotic puromycin. After en-
riching functional molecules of displayed peptides or
proteins, the sequence information can easily be re-
trieved by analyzing the attached mRNA. Using this ap-
proach, the frequency of the occurrence of ATP [11] or
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Germany mined. These studies indicated that functional proteins
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Universita¨tsklinikum Charite´ means.
We were interested in the de novo selection of pep-Schumannstraße 20-21
10098 Berlin tides that recognize a protein target that is bound and
affected by a diverse set of natural peptides at variousGermany
3Jerini AG epitopes. One prominent example is human -thrombin,
a key enzyme in blood coagulation [13] that modulatesInvalidenstraße 130
10115 Berlin procoagulant as well as anticoagulant processes. First,
the serine protease thrombin converts fibrinogen intoGermany
fibrin, which finally leads to clot formation, and second,
it regulates its own production level by activation of
factors V, VIII, and XI [14–16]. The structure and surfaceSummary
of thrombin has been intensively studied, and in addition
to the active site cleft, two main positively charged epi-Here we report the in vitro selection of novel small
topes termed the anion binding exosites have been iden-peptide motifs that bind to human -thrombin. We
tified: (1) the fibrinogen recognition exosite (FRE or exo-have applied mRNA display to select for thrombin
site-1) and (2) the heparin binding exosite (exosite-2)binding peptides from an unbiased library of 1.2  1011
[17]. Many natural thrombin inhibitors like heparin, hiru-different 35-mer peptides, each containing a random
din [18–20], hirugen [21], haemadin [22, 23], heparin co-sequence of 15 amino acids. Two clones showed bind-
factor II [24], and antithrombin III [25, 26], which bind toing affinities ranging from 166 to 520 nM. A conserved
either or both sites on the thrombin surface, have beenmotif of four amino acids, DPGR, was identified. Clot
identified and characterized and were subsequently en-formation of human plasma is inhibited by the selected
gineered [27]. They play an important role as anticoagu-clones, and they downregulate the thrombin-medi-
lants in a large variety of clinical applications. Of hightated activation of protein C. The identified peptide
clinical relevance is heparin, a polysulfated glycan thatmotifs do not share primary sequence similarities to
promotes the binding of heparin cofactor II and anti-any of the known natural thrombin binding motifs. As
thrombin III. Another exosite-2 binding protein is thenew inhibitors for human thrombin open interesting
platelet glycoprotein Ib [30], but its biological role haspossibilities in thrombosis research, our newly identi-
not been fully determined to date. Thrombomodulinfied peptides may provide further insights into this
binds to human thrombin on the surface of endothelialfield of investigation and may be possible candidates
cells and by the formation of the complex protein Cfor the development of new anti-thrombotic agents.
activation [28, 29] is accelerated. Table 1 summarizes
different proteins and SELEX-derived nucleic acids that
Introduction bind to -thrombin.
These examples indicate that human -thrombin is a
In vitro display techniques are powerful tools to identify protein recognized and affected by a wide variety of
polypeptides with desired features and functionalities different protein motifs. We have used in vitro selection
from random sequence libraries. There are now a num- of a library of mRNA-displayed peptides, restricted in
ber of methodologies available that allow the physical length but unbiased in their primary sequence, to isolate
and unambiguous connection of protein primary se- functional sequences that bind to human -thrombin.
quences with their encoding mRNAs. Techniques such The mRNA display molecules used in the selection com-
as phage [1, 2], ribosome [3–5], and mRNA display [6–10] prised a 15 amino acid long randomized region compa-
allow researchers to perform protein in vitro evolution rable to the length of identified protein motifs interacting
experiments using libraries of peptide and protein se- with -thrombin (see Table 1). One aspect we were par-
quences. With respect to library complexity and simplic- ticularly interested in was the question regarding the
ity and stability of the connection of genotype and phe- frequency of the occurrence of thrombin binding pep-
notype, mRNA display is among the most powerful tides in this library. Our study also addresses the ques-
approaches. The technique benefits from the covalent tion of how selected sequences compare with natural
linkage between the mRNA and its encoded polypep- ones with respect to primary sequence, the occurrence
of binding motifs, binding affinity, epitope selection, and
inhibitory activity. The selection of novel peptide ligands*Correspondence: m.famulok@uni-bonn.de
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Table 1. Binding Motifs of Different Ligands for -Thrombin
Name Interacting Sequence Reference
Antithrombin III 391-AGRSLNPNRVTFKA-404 [27]
DNA aptamer 1-GGTTGGTGTGGTTGG-15 [40, 56]
Fibrinogen
Fibrinopeptide A 52-WPFCSDEDWNY-62
Fibrinopeptide B 56-APSLRPAPPPISGGGYR-72 [51, 52]
Haemadin 46-EFEEFEIDEEEK-57 [22]
Heparin cofactor II 54-NDWIPEGEEDDDYLDLEKIFSEDDDYI-75 [24, 53]
Hirudin 54-DFEEIPEEYLQ-65 [19, 20]
Platelet glycoprotein Ib 272-DTDLYDYYPEE-282 [57, 58]
RNA aptamer 1-UCCGGAUCGAAGUUAGUAGGCGGA-24 [36]
Thrombomodulin 415-LDDGFICTDIDECEN-429 [42, 51, 54, 55]
Numbers refer to the positions of residues within epitopes that contact -thrombin.
to human -thrombin modulating its diverse interactions tions. PCR amplification of these molecules yielded the
starting material for the next round of selection. In roundshould provide further insight into the multifunctional
role of the protease. 3, a preselection against a nonderivatized matrix was
introduced to eliminate possible matrix binders. The
wash volume was slightly increased in round 5 to 15Results and Discussion
CV, and when the binding reached 42% in this fifth round
(Figure 1B), the stringency was increased to 25 CV inLibrary Design
We designed and synthesized a DNA library encoding a the succeeding cycle followed by a decrease in binding
to approximately 18%. As expected, binding went fur-35-mer amino acid sequence containing 15 randomized
amino acid positions [31] (Figure 1A). Similar to the work ther down to approximately 10% with 200 CV of wash
volume in cycle 6. In the subsequent rounds of selection,of Baggio et al. [32] and Cujec et al. [33], the codon
triplets for each amino acid were not subject to any bias binding rose again and reached 25% in round 10. The
eluted molecules were then amplified by PCR and con-in terms of imposing  helix or  sheet patterning. After
the translation initiation site, we introduced TGT as a secutively cloned and sequenced. Seventy-two clones
were randomly chosen for analysis. The obtained clonescodon for a fixed cysteine residue, allowing the possibil-
ity of forming conformational constraints via disulfide resulted in 45 different sequences (Figure 1C), but more
than 60% contained a highly conserved four amino acidbridges. The random region was designed for low stop
codon frequency and increased cysteine probability sequence motif, DPGR. As shown in Figure 1C, five
sequences appeared in duplicates and eight other se-(1 Cys within the random region). To facilitate purifica-
tion on Ni2-NTA agarose, a 6 histidine-tag (his6) was quences were identical, adding four with only point mu-
tations. The DPGR motif could be found at almost everyinserted. By introducing the his6 tag downstream of the
randomized region, we only purified molecules that did position of the random sequence, although a position
closer to the C-terminal end seems to be preferred. Fromnot contain stop codons or frame shifts. The DNA library
was transcribed using T7 RNA polymerase, and the ob- this analysis we conclude that this motif is obviously
crucial for the recognition and binding between thetained RNA was linked to a synthetic DNA oligonucleo-
tide bearing the puromycin moiety at its 3 end. The clones and -thrombin. Furthermore, 24 different se-
quences (42%) contained a second cysteine residue.mRNAs linked to puromycin were in vitro translated, and
approximately 1.2  1011 different peptide displaying Interestingly, none of the selected sequences showed
any primary sequence similarity to the natural thrombinmolecules were obtained after purification on oligo-dT
cellulose, Ni-NTA agarose, and reverse transcription. A binding motifs (Table 1).
randomized region of 15 amino acids theoretically yields
3  1019 (2015) unique sequences. This sequence space Binding Studies
To characterize the obtained sequences, two differentis only partially covered by the synthesized library but
still resembles the potential repertoire of the human clones, designated as T10-11 (sequence of the random
region: ERNYNDFCDPGRVGL) and T10-39 (FFDRYDSantibody complexity.
ARDPGRLL) from the enriched round 10 pool were cho-
sen for further studies. As a control sequence, cloneSelection
Binders to human -thrombin were enriched after 10 T10-35 (WQRCGMAEFIWHFQW) was chosen from the
selected pool, and from the unselected starting pool acycles of selection and amplification. For the selection
a cyanogenbromide-activated sepharose matrix was sequence named P-11 (VRIAASRISTNNKYF) was se-
lected. T10-11 and T10-39 both contain the DPGR motif,derivatized with human -thrombin. Using this method,
the protein is statistically coupled to the matrix, which and T10-11 additionally features a second internal cys-
teine residue. Clone T10-35 contains neither the DPGRallows screening of the entire exposed surface. The
mRNA-display library (11 pmol) was then incubated with motif at any position nor the cysteine residue. First,
the RNA of each sequence was prepared and directlythe immobilized thrombin. After appropriate washes (10
column volumes [CV] in the first four rounds), the re- (without ligation to the puromycin linker) subjected to
in vitro translation in the presence of 35S-labeled methio-tained molecules were eluted under denaturing condi-
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very weak binding to the matrix. Removal of the his6
tag has only minor effects and leads to a decrease in the
relative binding activity by approximately 15%. Although
the elimination of the his6 tag does not decisively influ-
ence the binding, contribution of the constant amino
acid regions cannot be completely excluded.
Competition studies under the described conditions
were performed adding free thrombin to the binding
assays. Increasing free thrombin reduces the binding of
the free peptide to the matrix (data not shown). The
apparent inhibition constants (Ki) for thrombin were de-
termined to be 295 nM and 236 nM for the T10-11 and
the T10-11 His construct, respectively. Thrombin shows
Ki’s of 228 nM and 457 nM for the T10-39 and the T10-
39 His constructs, respectively. The relatively high Ki
of 450 nM for the T10-39 His construct, compared
to 250 nM for the others, suggests strong binding of
this free peptide to the matrix because high levels of
free thrombin are necessary to compete the binding. To
determine the dissociation constants of both clones,
the 29-mer peptides of the T10-11 His and T10-39 His
constructs were custom synthesized and coupled to
surface plasmon resonance sensor chips. Thrombin was
used as analyte at increasing concentrations (1–2500
nM). Dissociation constants were then calculated by the
BIAevaluation software using steady-state affinity curve
fits (Figures 2B and 2C). Kd values of 520  6 nM for
T10-11 and 166  18 nM for T10-39 were determined.
Although clone T10-39 is not the most abundant one, it
shows better binding to thrombin, which is in accor-
dance to the result of the relative binding studies and
the included determination of the apparent inhibition
constant. It further suggests that the formation of a disul-
fide bridge is not crucial for binding, because clone
T10-39, in contrast to clone T10-11, does not contain a
second cysteine. As a control we used human neutrophil
Figure 1. Library Design and Course of Selection elastase, which is related to the protease thrombin, and
(A) Schematic drawing of the library design. The randomized region no binding to the immobilized selected peptides was
is shaded black where X represents an amino acid residue. Constant detected under these conditions up to concentrations
regions are shaded gray, and the fixed cysteine residue and the
of 5 M elastase (data not shown).histidine-tag are shaded light gray.
(B) Course of selection. Bars represent the percentage of radioactiv-
ity that bound to the column matrix in each cycle. Below, the number
of each cycle is given and the volume of wash buffer in column Epitope Mapping
volumes (CV) used in each cycle. We next sought to narrow down which epitope of throm-
(C) Analysis of the obtained sequences from round 10 (only the 15 bin is recognized by the small peptides. We performed
randomized amino acids are shown). More than 60% of the clones competition binding studies in solution by using hirudin,
contain the 4 amino acid DPGR motif. Numbers in brackets indicate
hirugen (amino acids 54–65 of hirudin in the sulfatedhow often clones were found.
and nonsulfated modification), and antithrombin III
among the natural thrombin binding peptides shown in
Table 1 as representatives of exosite-1 and -2 binders.nine to gain the free peptide. According to Barrick et al.
[34], the relative binding of the clones were determined We also investigated the ability of the SELEX-derived
DNA- [35] and the 24 nucleotide RNA aptamer 16.24and percentages of bound free peptide were calculated
by phosphorimager integration (Figure 2A). To investi- [36] to compete with the peptide aptamers for thrombin
binding. Peptides T10-11 and T10-39 were immobilizedgate whether the his6 tag is involved in the binding,
sequences lacking the tag (termed His) were prepared on the flow-cell and incubated with 50 nM thrombin,
and increasing concentrations of the different thrombinand treated the same way as described above. The
starting pool and the control sequence P-11 do not bind binders were added (for Supplemental Data, contact
Chemistry and Biology at chembiol@cell.com). The ob-to the thrombin-derivatized matrix, whereas the se-
lected clones T10-11 and T10-39 and the his6 truncated tained responses were normalized to the binding with-
out competitor and curves fitted using the program Ori-versions show retention on the thrombin sepharose
ranging from 50% to 85% based on a normalized level gin 6.1 (OriginLab Corporation, Northampton, MA).
Apparent competition constants (Ki’s) are listed in Tableregarding the radioactivity of the free peptide. Sequence
T10-35, which derived from the enriched pool, shows 2. Hirudin showed a Ki of550 nM, whereas competition
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Figure 2. Binding Studies and Kd Determination
(A) Bars illustrate the binding of the free 35S-labeled peptides to the thrombin-derivatized matrix. Gels of the crude lysate (CL) and the eluted
peptide (elu) are shown below each construct.
(B) and (C) illustrate the Kd determination of clone T10-11 and T10-39, respectively. In the upper part, the binding curves (time versus
response difference in response units [RU]) of thrombin on immobilized peptides are shown. The lower level shows the steady-state curve
fits (concentration of peptides against RU). The arrowheads indicate the increasing thrombin concentrations (1–2500 nM). The Kd values of
T10-11 and T10-39 were determined to be 520 nM and 166 nM, respectively.
by the sulfated hirugen is 1.4- to 1.6-fold weaker for in another competition assay in which immobilized
thrombomodulin and thrombin were used as analytes.T10-11 and T10-39, respectively, and 3.3- to 5.9-fold
weaker for the nonsulfated peptide (Table 2). The Ki of Here again the DNA aptamer blocked the interaction of
those two proteins with a lower Ki than hirudin (data notantithrombin III is 8.1- to 9-fold higher than that of hiru-
din. Interestingly, the DNA aptamer can compete with shown). The RNA aptamer exhibited a similar Ki as the
DNA aptamer, although competition with heparin sug-the selected peptides much more efficiently than hiru-
din, although it binds to the thrombin exosite with a Kd gested that this RNA binds the electropositive heparin
binding site of thrombin with higher preference than theof only 200 nM [35], which is a considerably weaker
affinity than that of hirudin. The same trend is observed exosite-1 [36]. At present, we cannot explain why both
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Table 2. Apparent Competition Constants of Various Thrombin
Binders with Immobilized T10-11 and T10-39
Apparent Competition Constants (nM)
Inhibitor T10-11 T10-39
Hirudin 524  29 575  16
Hirugen 1721  133 3413  299
Hirugen (SO4) 743  121 933  211
DNA aptamer 47  5 57  3
RNA aptamer 49  4 59  3
Antithrombin III 4269  366 5214  296
The table shows competition constants determined by surface plas-
mon resonance. 50 nM thrombin was incubated with increasing
concentrations of thrombin binders. The obtained curves (see Sup-
plemental Figure S1) were fitted in Origin 6.1 to obtain the corre-
sponding apparent binding competition constants (Ki’s).
aptamers compete with similar activity with our selected
peptides for thrombin binding although they bind to
different surfaces of the protein. Their activity is specific
because random nucleic acids show no effect in the
same experimental setup (data not shown). It is possible
that the comparable Ki’s reflect the marked differences
in the Kd of both aptamers. While the Kd of the DNA
aptamer is reported to be around 200 nM [35], the 16.24
RNA aptamer binds thrombin with a Kd of 9 nM [36].
Furthermore, it has been reported that serpins, when
complexed to exosite-2, allosterically disorganize exo-
site-1 [37, 38]. It is possible that the binding of 16.24
does the same, thereby affecting the binding of the se-
lected peptides at a distal site.
In order to interpret the other competition data shown
Figure 3. Binding of Inhibitors to Thrombinin Table 2, we evaluated structural data available for the
(A) The figure shows the structure of -thrombin (gray) with thevarious thrombin binding targets used as competitors
active site in magenta and exosite-1 residues in orange.
in Table 2. These data are summarized in Figure 3. Figure (B) Thrombin in exactly the same orientation including the superim-
3A shows thrombin without the complexed ligands, and posed structures complexed hirudin (red), thrombomodulin (yellow),
exosite-1 residues highlighted in orange. Figure 3B and the DNA aptamer (blue). Structures were obtained from the
available data of 4htc [17, 19, 39], 1dx5 [42], and 1hap [40] andshows thrombin in exactly the same orientation as in
fitted using the program package Sybyl 6.8 on a Silicon GraphicsFigure 3A with hirudin (red) [39], the DNA aptamer (blue)
Octane workstation. All three ligands share a small surface of over-[40, 41], and thrombomodulin (yellow) [42] superim-
lapping contacts on the thrombin surface.
posed. While all three ligands make contacts to exo-
site-1 residues, it appears that the degree to which the
surface of exosite-1 is utilized for binding is different
duced (3- to 9-fold weaker) binding to 	-thrombin, which
for each ligand. The surface within exosite-1 in which
lacks the exosite-1 (data not shown), indicating that
contacts of each of the three ligands overlap is rather
exosite-1 residues participate in binding of these pep-
small. Apart from these overlapping exosite-1 contacts,
tides to some extent.
the binding sites of the three ligands vary considerably.
It is evident that the binding site of the DNA aptamer,
which shows enhanced competition in our studies, is SPOT Analysis
After we have shown the binding of the selected pep-located fairly apart from that of the other two ligands.
Taken together, these data suggest that our selected tides, we were interested in the minimal motifs and
which amino acids are necessary for the interaction.peptide aptamers target a site on thrombin that is more
closely matched by the DNA aptamer than by hirudin, The peptides of clone T10-11 and T10-39 were subject
to further analysis using the SPOT technique (reviewedthrombomodulin, or antithrombin III. As hirudin and the
DNA aptamer both have contacts with residues within in Reineke et al. [43] and references therein). Peptides
of 13 amino acids length were synthesized on a cellulosethe hirudin/fibrinogen binding site (exosite-1), but the
DNA aptamer is a more active competitor, it is likely membrane, each sequence overlapping one amino acid
of the original sequence. Therefore, in total 17 spots ofthat the small peptides interact with parts of the same
surface that is also contacted by the DNA aptamer. 13-mers that correspond to residues 1–13, 2–14, 3–15,
… 17–29, spanning the entire 29 amino acid sequence,Whether this interaction surface also includes exosite-1
residues cannot be said with certainty. However, we were synthesized. The membrane was then treated as
described in the Experimental Procedures section andfound that T10-11 and T10-39 show significantly re-
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Figure 4. SPOT Analysis
(A) Overlapping peptide scans of clone T10-
11 (rows a and b) and clone T10-39 (rows c
and d). Peptides were prepared on cellulose
membranes as 13-mers (numbers indicate
each of the 17 different single sequences)
covering the whole 29 amino acids of the sin-
gle clones. Rows a and c indicate the original
sequence, and rows b and d illustrate the
binding pattern with cysteine exchanged
against serine.
(B) Substitution scan of clone T10-11 and (C)
of clone T10-39. Each minimal motif is given
in the vertical panels. Each row starts with the
wild-type (wt) sequence and the next spots
indicate amino acid exchanges against the
amino acids depicted in the horizontal panels.
documented on X-ray films (Figure 4A). Analysis of the truncated from the N- or the C-terminal end or both were
synthesized in parallel and spotted individually on a cel-overlapping regions revealed that in clone T10-11
(MGMGTCERNYNDFCDPGRVGLSGSSMSGS), the min- lulose membrane. For this “length scan,” the minimal
motif plus the flanking amino acids of each clone wereimal sequence required for thrombin binding is a 7 amino
acid fragment (underlined; constant amino acids are spotted on a cellulose membrane. Analysis of the bind-
ing pattern revealed that the length of the peptide thatshown in italics) (Figure 4A, a). For clone T10-39
(MGMGTCFFDRYDSARDPGRLLSGSSMSGS), this frag- still binds to -thrombin could be cut down from 13
amino acids to only the four amino acids of the DPGRment could be determined to be as small as 6 amino
acids (underlined) (Figure 4A, c). Both minimal motifs motif and one flanking amino acid at either side (data
not shown). To further investigate which amino acidscontain the amino acid motif DPGR, which reflects the
observation from the sequence analysis. Exchanges of are crucial for binding, we performed a “substitution
scan” [44] of clones T10-11 and T10-39. The sequencethe cysteine residues in both clones against serine do
not alter the binding pattern (cf. Figure 4A, b/d), which containing the exchanged serine residue was chosen for
clone T10-11 because cysteine might cause oxidativesuggests that the formation of a disulfide bond is not
necessary for thrombin recognition. This finding is fur- problems in the setup. For the substitution scan, again
the minimal motif of each clone was spotted on a cellu-ther supported because cyclization of the membrane
bound peptides of clone T10-11 shows no difference to lose membrane and each single amino acid was then
sequentially substituted against all 19 other ones. Thethe pattern obtained from the linear peptides (data not
shown). Other SPOT peptides that were sequentially obtained binding pattern for clone T10-11 (Figure 4B)
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reveals that the first three C-terminal and the last four peptides. Thrombin activity was measured using a chro-
mogenic substrate, S-2238. Upon the thrombin-cata-N-terminal amino acids of T10-11 can be exchanged
against almost any other of the 20, resulting in only lyzed cleavage of the substrate, a nitroaniline derivative
is released, which can be detected by measuring theminor differences in the binding level. In contrast, the
phenylalanine residue at position 4 shows exchange optical density (OD). Therefore, thrombin was mixed
with the peptides in varying concentrations, and theability only with few other residues like alanine, glycine,
histidine, asparagine, serine, or tyrosine. Interestingly, thrombin activity analyzed by the liberation of the chro-
mophore (Figure 5A). The peptides T10-11 and T10-39position 5 (Ser) loses its binding capability when it is
exchanged against proline, suggesting that proline com- as well as the control peptide P-11 showed no influence
on the thrombin activity. Neither did the constructspletely breaks the structure of the peptide. Clone T10-
39 (Figure 4C) shows a very similar binding pattern. The M8T10-11, M7T10-11, M8T10-39, the DNA aptamer, and
antithrombin III (data not shown). Only hirudin as anN- and C-terminal amino acids are relatively insensitive
toward changes. The arginine residue at position 6 can active site binder blocked the enzymatic activity in this
assay, as expected. This indicates that the interactiononly be substituted by a lysine, which can be explained
because of the similar structure of the side chain. The of the peptides with the thrombin molecule does not
interfere with the active site. To analyze whether thehighly conserved DPGR motif (Figure 1C) is very sensi-
tive to exchanges, and binding is only restored if amino small peptides are able to inhibit clot formation, mea-
surements with a coagulometer using human plasmaacids are exchanged against each other. To reestablish
binding, aspartic acid has to be exchanged against were performed (Figure 5B). Standard clotting time of
human plasma with added thrombin was15 s. Increas-aspartic acid, proline against proline, glycine against
glycine, and finally arginine against arginine. Within ing concentrations (0.2 to 80 M) of the small peptides
were added and thrombin clotting times determined.those four amino acids, aspartic acid can be partially
substituted by arginine and the proline residue by the Both T10-11 and T10-39 show significant elongation of
the clotting time up to 5-fold at a concentration of 80M,hydrophobic amino acids phenylalanine, isoleucine, and
valine. Glycine is crucial at its position and the arginine whereas the short constructs M8T10-11 and M7T10-11
do not decisively influence the clotting time (data notresidue can be exchanged against phenylalanine. Fur-
thermore, in the two leucine residues following the shown). Only M8T10-39 doubles the time until clot for-
mation at 80M (data not shown). The control sequenceDPGR motif in clone T10-39, two gaps appear. The first
leucine shows no binding any more if it is substituted P-11 shows no effect. A recently selected peptide that
binds coagulation factor VIIa [46] shows a similar effectby proline, the second if it is substituted by glutamic
acid. It can be seen that the conserved DPGR motif is as it prolongs the clotting time up to 5-fold at a concen-
tration of 100M. We conclude that the selected peptidevery susceptible to substitutions, which indicates that
those four amino acids are crucial for thrombin recog- sequences can influence thrombin activity by blocking
the interaction between fibrinogen and thrombin. Innition.
The obtained minimal sequences of the two clones comparison with hirudin or the DNA aptamer, which
are able to completely inhibit clotting of plasma, ourwere custom synthesized, comprising either 7 or 8
amino acids. Sequences Ac-FSDPGRVG-NH2 (desig- selected peptides perform less well. However, since the
selection protocol was designed for binding, it is inter-nated as M8T10-11) and Ac-SDPGRVG-NH2 (M7T10-11)
from clone T10-11 and the sequence Ac-ARDPGRLLS- esting to note that our peptides interact at the same
epitope as the DNA aptamer.NH2 (M8T10-39) from clone T10-39 were synthesized
either regularly N-terminal free/C-terminally acetylated To analyze whether the selected peptides alter the
formation of the complex between thrombin and throm-(Ac) or N-terminal free/C-terminally biotinylated bearing
two -alanine residues between the biotin moiety and bomodulin (TM), which then activates protein C, we per-
formed inhibition studies (Figure 5C). Thrombin and TMthe first amino acid. The biotinylated peptides were used
in surface plasmon resonance studies on streptavidin were premixed and the peptides added at increasing
concentrations. Protein C was included and the produc-sensor chips. Unfortunately, no significant interaction
between the minimal sequences and thrombin could be tion of activated protein C was measured using a chro-
mogenic substrate, S-2366. We determined that both ofdetected. It is known that low-affinity interactions can
the selected peptides decrease the protein C activationbe detected by the SPOT technique because of a very
to 10% of the original level at a concentration of 100high local concentration of the peptide and the signal
M. The apparent inhibition constant (Ki) of protein Camplification by the horseradish peroxidase [45]. It is
activation by the peptides were determined to be 5 andalso possible that the streptavidin surface of the sensor
8 M for T10-11 and T10-39, respectively. A previouslychip may interfere with the binding event. In any case,
rationally designed peptide inhibiting the interaction be-this result shows that the minimal motif alone is neces-
tween thrombin and thrombomodulin revealed an ap-sary but not sufficient for high-affinity interaction with
parent Ki of only 94 M [47]. Compared to our selectedthrombin. Flanking amino acids are required to increase
peptides, the DNA aptamer showed nearly the samethe binding affinity between the selected peptides and
activity in blocking protein C activation (Ki 
 4 M). Thistheir target.
finding is in accordance with the epitope-mapping data,
which suggest that the selected peptides contact throm-
Functional Studies bin at a similar site as the DNA aptamer. The control
As thrombin comprises a large variety of functions, we peptide P-11 seems to have some unspecific effect at
high concentrations but does not decisively influenceinvestigated how its activity is influenced by the selected
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the protein C activation. The Ki of P-11, which is difficult
to determine, was calculated to be at least 150 M.
These observations are in accordance with the pro-
posed binding site of T10-11 and T10-39 at or in close
proximity of exosite-1.
Significance
Thrombin plays an important role in various reactions
within the blood clotting cascade. In this work we
present the evolution and identification of thrombin
binding peptides out of a entirely randomized peptide
library. We show that the selection of functional amino
acid motifs out of a random library comprising 15
amino acids in length with a diversity of 1.2  1011,
which reflects the human antibody repertoire, suc-
cessfully leads to functional sequences. The selection
resulted in a highly conserved amino acid motif con-
sisting of only four amino acids, namely DPGR. The
evolved binding motifs, however, show no similarity
with other naturally occurring protein domains binding
to human -thrombin. Thus, in vitro selection strate-
gies like mRNA display allow the identification of novel,
nonnatural functional sequences that can be used to
investigate how protein-protein interactions are orga-
nized. Our data are in accordance with the notion that
the selected peptides target thrombin at a similar site
as the DNA aptamer. Natural thrombin binders can
be found to contact either epitope of the thrombin
molecule. Although the binding affinity is not as high
as of natural proteins, we could demonstrate that the
selected sequences are able to influence the thrombin
activity by either prolonging the clotting time of human
plasma or by downregulating protein C activation. As
in vitro selection methods are open to find solutions
to almost every desired functionality, this study may
contribute to the identification of new and potent regu-
lators of the blood coagulation cascade.
Experimental Procedures
Library Preparation
Approximately 4 nmol of the 99-mer ssDNA template (5-CTATTTA
CAATTACAATGGGTATGGGTACCTGT56756756756756756756756
7567567567567567567567TCCGGATCCCATCATCATCAC-3) en-
coding 15 random amino acids and containing a 5 KpnI and 3
Figure 5. Functional Studies BamHI restriction site (underlined) and encoding the amino acid
sequence H2N-MGMGTC(X)15SGSHHHHHHSMSGS-CO2H (X is aUsed peptides are T10-11 (filled circle), T10-39 (filled square), and
random amino acid, cf. Figure 1A) was synthesized by standardthe control sequence P-11 (filled triangle).
phosphoramidite oligonucleotide synthesis. The numbers 5, 6, and(A) Proteolytic activity assay of thrombin, measured by liberation
7 in the DNA sequence represent phosphoramidite mixtures thatof the chromophore from chromogenic substrate S-2238. Peptide
were optimized for each codon position using a computer algorithmconcentration is plotted against relative activity. As a positive con-
[48]. According to Pollard et al. [49], the phosphoramidites of A, G,trol, hirudin (filled diamond) was included in the analysis.
C, and T were dissolved in acetonitrile and then mixed for each(B) Clotting analysis of human plasma. Peptide concentration is
codon position as follows: 5, A 19.2%, G 23.4%, C 23.4%, T 34.0%;plotted against the clotting time. At a concentration of peptides
6, A 33.2%, G 32.9%, C 13.5%, T 20.4%; and 7, A 0.00%, G 31.0%,T10-11 and T10-39 of 80 M, clotting time is elongated almost
C 34.5%, T 34.5%. PCR amplification of the synthesized oligomer5-fold. P-11 shows no effect.
using the following 55-mer 5-primer containing the T7 RNA poly-(C) Protein C activation. Upon binding to thrombomodulin, thrombin
merase promotor (underlined) and sequences required for transla-activates protein C. Peptide concentration is plotted against the
tion initiation (5-TAATACGACTCACTATAGGGACAATTACTATTTArelative initial velocity (first 6 min) of the protein C activation, mea-
CAATTACAATGGGTATGGGTA-3) and the 41-mer 3-primer contain-sured by liberation of the chromophore from chromogenic substrate
ing the sequence for the 6 histidine tag and ligation sites (5-ACTS-2366. T10-11 and T10-39 show strong effects by decreasing the
GCCGCTCATACTATGGTGGTGATGATGATGGGATCCGG-3)production level of protein C; P-11 does not significantly influence
yielded the dsDNA template that was used for transcription with T7this reaction. As a positive control, the DNA aptamer (filled inverted
RNA polymerase (Stratagene, Amsterdam, The Netherlands). Thetriangle) was used in this assay showing slightly higher efficacy in
obtained RNA was ligated to the DNA oligo bearing the puromycininhibiting protein C activation than the selected peptides.
moiety at its 3 end via splint-mediated blunt end ligation using T4
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DNA ligase and T4 RNA ligase (New England Biolabs, Frankfurt, thrombin (concentrations ranging from 1 to 2500 nM) were obtained
and dissociation constants determined by steady-state affinityGermany). The ligated product was gel purified and subject to an
8 ml in vitro translation using rabbit reticulocyte lysate (Calbiochem- curve fits. To map the epitope which the peptides bind to, competi-
tion studies in solution were performed using hirudin (full-length,Novabiochem, Schwalbach, Germany) in the presence of 35S-labeled
methionine (Amersham Biosciences, Freiburg, Germany) for the first Roche, Mannheim, Germany), hirudin peptide (amino acids 54–65,
nonsulfated and sulfated, Sigma, Taufkirchen, Germany), and anti-cycle. Volume was scaled down to 1 ml for all subsequent cycles.
The resulting mRNA display molecules were purified on oligo-dT thrombin III (Roche, Mannheim, Germany). Thrombin was used at a
constant concentration of 50 nM, and concentrations of the compet-cellulose (Amersham Biosciences, Freiburg, Germany) and Ni-NTA
agarose (Qiagen, Hilden, Germany). After reverse transcription, the itors were varied from 1 to 2500 nM. Further peptides representing
either 7 or 8 amino acids of the minimal motifs, either C-terminallycomplexity of the mRNA display peptides was calculated to be 1.2
1011 comparing the number of 35S counts of the purified fusions to biotinylated or acetylated, were synthesized and used in the compe-
tition experiments.the counts of the total [35S]methionine present in the translation
mixture.
SPOT AanalysisSelection
Peptide spots were synthesized by JERINI AG, Berlin, Germany.Human -thrombin (Cell Systems, St. Katharinen, Germany) was
The cellulose membrane was blocked overnight with 10% blockingcoupled to CNBr-activated sepharose 4B (Amersham Biosciences,
reagent (Roche, Mannheim, Germany), washed with T-TBS (50 mMFreiburg, Germany) at 1 mg per 1 ml of swollen gel and the concen-
Tris, 137 mM NaCl, 2.7 mM KCl, 0.05% Tween 20 [pH 8.0]), and thentration on the matrix was calculated to be 27M. The purified mRNA
incubated with human -thrombin (10 g/ml) for 75 min at 25Cdisplay peptides were exchanged into selection buffer (140 mM
followed by an incubation with a murine anti-thrombin antibody (CellNaCl, 4 mM MgCl2, 5 mM KCl, 20 mM HEPES, 2 mM glutathione,
Systems, St. Katharinen, Germany) at 1 g/ml for 75 min at 25C.1 mM glutathione-disulfide, 0.1 mM EDTA, 0.25% Triton X-100 [pH
Finally, the membrane was incubated with a horseradish peroxidase7.4]) over a preequilibrated NAP-10 column, which was blocked with
coupled rabbit anti-mouse antibody (DAKO, Glostrup, Denmark) at1 mg/ml salmon sperm DNA (Invitrogen, Karlsruhe, Germany) and
a dilution of 1:1000 for 75 min at 25C. After 3 washes with T-TBS,0.1 mg/ml BSA (Calbiochem, San Diego, CA). Incubation was then
the membrane was developed using ECL reagent (Amersham Bio-performed with 150 l of thrombin matrix for 1 hr at 25C with slight
sciences) for 1.5 min and immediately exposed to a X-ray film for 5 s.agitation. For cycles 2 onward, a NAP-5 column and only 100 l of
matrix were used. After appropriate washes with selection buffer
(see Figure 1B), bound peptides were eluted with elution buffer (4 M
Clotting Studiesurea, 0.5% SDS), desalted, precipitated, and subsequently PCR
Thrombin clotting times were measured with a KC10 coagulometeramplified.
(Amelung, Lemgo, Germany). One hundred microliters of frozen-
thawed plasma (kind gift of Dr. B. Po¨tzsch) was preincubated at
Sequence Analysis
37C for 2 min. Then 100 l of a solution containing 0.25 NIH units
Amplified DNA from round 10 was digested with restriction enzymes
human -thrombin, the inhibitor peptides, and CaCl2 were added toKpnI and BamHI (New England Biolabs, Frankfurt, Germany) ac-
give final concentrations of the peptides between 0.2 and 80 M
cording to manufactures instructions and ligated into a complemen-
and 6.25 mM CaCl2. All experiments were performed at least intary cut pGEM-4Z plasmid (Promega, Mannheim, Germany). E. coli
triplicates.
DH10B cells were transformed and 72 colonies were randomly
picked and grown up. In parallel dsDNA from the starting pool was
treated the same way as described above and 36 sequences were Chromogenic Assays
analyzed (data not shown). The purified vectors were sequenced The activity of thrombin was measured with the chromogenic sub-
using Sequenase (Amersham Biosciences, Freiburg, Germany) and strate S-2238 (Haemochrom Diagnostica, Essen, Germany). One
the dideoxy method in the presence of [-35S]dATP. DNA sequences hundred fifty microliters of 50 mM Tris (pH 8.3) containing 0.5 NIH
for further analysis were commercially synthesized and PCR ampli- units human -thrombin and increasing concentrations of the pep-
fied using the primers mentioned in the library design section. For tides were preincubated at 37C for 5 min. Then 50 l of a 2 mM
the truncated versions of the peptides lacking the his6 tag, a short aqueous solution of S-2238, prewarmed to 37C for 5 min, was
24-mer 3-primer (5-ACT GCC GCT CAT ACT GGA TCC GGA-3) added and the measurement immediately started in a 96-well plate
was used. reader (Dynatech Laboratories, Chantilly, VA) at 405 nm. Relative
initial reaction velocities, corrected by a control not containing a
Binding Studies peptide, were plotted against the different peptide concentrations
To determine the relative binding of the selected peptides or their (ranging from 0.1 to 20M). Reactions were performed in duplicates.
truncated versions, the dsDNA of the single clones or the pool Inhibition of protein C activation was determined using the chro-
was transcribed and the purified RNA directly subject to in vitro mogenic substrate S-2366, which is specific for activated protein
translation without ligation to the puromycin linker. According to a C (aPC). A standard reaction in a microtiter plate contained 3.7 nM
slightly modified protocol of Barrick et al. [34], a 20 l aliquot of the thrombin and 2 nM rabbit lung thrombomodulin in 50 mM Tris buffer
crude lysate containing the free translated peptide was mixed with (pH 7). This mix was preincubated at 37C for 2 min. Then the
selection buffer and incubated with the thrombin matrix for 1 hr at peptides were added in concentrations ranging from 5 to 100 M,
25C with agitation. After draining for flow through, the sepharose followed by a 5 min incubation at 37C. Final calcium concentration
was washed with selection buffer and then eluted with tricine-SDS was adjusted to 2.5 mM and protein C was added to give 887 nM.
loading buffer (50 mM Tris, 12% glycerol, 4% SDS, 0.1 M DTT [pH After 15 min at 37C, the chromogenic substrate was added and
6.8]). Identical aliquots of the elution fraction and the crude lysate the measurement of the cleavage reaction immediately started in
were loaded onto a 12% tricine-SDS gel [50], run at 125 V, fixed, a plate reader at 405 nm. All measurements were performed in
dried, and quantified using a phosphorimager (FUJI FLA3000). For duplicates.
competition studies, free human -thrombin (10 to 5000 nM) was
added to the samples, which were treated the same way as de-
scribed above. Ki values were calculated as a function of percent Model Generation
binding inhibited versus the concentration of free thrombin. The model of the different inhibitors on thrombin was generated on
a Silicon Graphics Octane Workstation (400 MHz R12k CPU, 1 GB
RAM) running under SGI Irix 6.5 using the program package SybylKd Determination and Epitope Mapping
Peptides of clones T10-11 and T10-39 lacking the his6 tag were 6.8 (Tripos Inc., St. Louis, MO). The available structural data of the
complexes of thrombin with hirudin (4htc) [39], the DNA aptamersynthesized by standard Fmoc-strategy and subsequently immobi-
lized on a BIAcore CM5 chip using standard EDC/NHS coupling (1hap) [40, 41], and thrombomodulin (1dx5) [42] were superimposed
and colored.according to the manufactures instructions. Binding curves for
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